Floatz logo

Irinotecan

Digestive System Neuroendocrine Tumor, Grade 1/2

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Digestive System Neuroendocrine Tumor, Grade 1/2 cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Mayo Clinic
Phase 2/3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
Xaliplatin
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2/3BB
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
National Cancer Institute (NCI)
Phase 3BB
Temsirolimus
National Cancer Institute (NCI)
Phase 2BB

View all 43 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerActive
BBB
Indicative · Phase 4
78 / 100
View asset →
exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →